fosamprenavir has been researched along with carbamates in 149 studies
| Studies (fosamprenavir) | Trials (fosamprenavir) | Recent Studies (post-2010) (fosamprenavir) | Studies (carbamates) | Trials (carbamates) | Recent Studies (post-2010) (carbamates) |
|---|---|---|---|---|---|
| 174 | 55 | 37 | 13,717 | 985 | 4,744 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 103 (69.13) | 29.6817 |
| 2010's | 43 (28.86) | 24.3611 |
| 2020's | 3 (2.01) | 2.80 |
| Authors | Studies |
|---|---|
| Gatell, JM | 1 |
| Corbett, AH; Kashuba, AD | 1 |
| Bye, C; Falcoz, C; Fuder, H; Hardman, TC; Jenkins, JM; Kenney, KB; Prince, WT; Studenberg, S | 1 |
| Gallant, JE | 1 |
| Chaudry, NI; Eron, JJ; Fiscus, SA; Kashuba, AD; Naderer, OJ; Pereira, AS; Wire, MB | 1 |
| Huff, B | 1 |
| Murphy, RL | 1 |
| Hayashi, Y; Ito, T; Kimura, T; Kiso, Y; Matsumoto, H; Sohma, Y | 1 |
| Arasteh, K; Eron, J; Millard, J; Naderer, OJ; Pollard, RB; Raffi, F; Stellbrink, HJ; Teofilo, E; Wire, MB; Wood, R; Yeo, J | 1 |
| Boghossian, J; Gray, GE; Millard, JM; Nadler, JP; Quinones, AR; Rodriguez-French, A; Sepulveda, GE; Wannamaker, PG | 1 |
| Boyle, BA | 1 |
| Pham, PA | 1 |
| Baker, CT; Furfine, ES; Hale, MR; Reynolds, DJ; Salisbury, JA; Searle, AD; Spaltenstein, A; Studenberg, SD; Todd, D; Tung, RD | 1 |
| Ballow, C; Hendrix, CW; Lou, Y; Piliero, PJ; Preston, SL; Stein, DS; Wire, MB | 1 |
| Elston, RC; MacManus, S; Richards, N; Snowden, W; White, S; Yates, PJ | 1 |
| Nadler, J | 1 |
| DeGoey, DA; Randolph, JT | 1 |
| Bellos, NC; DeJesus, E; Garris, C; Gathe, JC; Gladysz, A; Ive, P; Schürmann, D; Wood, R; Yeo, J | 1 |
| Honda, Y; Izawa, K; Katayama, S; Kishibata, N; Kojima, M; Suzuki, T | 1 |
| Becker, S; Thornton, L | 1 |
| Chapman, TM; Perry, CM; Plosker, GL | 1 |
| Back, D; Boffito, M; Dickinson, L; Fletcher, C; Gazzard, B; Higgs, C; Hill, A; Moyle, G; Nelson, M; Pozniak, A | 1 |
| Baker, KL; Ford, SL; Lou, Y; Stein, DS; Wire, MB | 1 |
| Acosta, EP; Collier, AC; Downey, GF; Eshleman, SH; Kashuba, AD; Klingman, K; Mellors, JW; Scott, TR; Tierney, C; Vergis, EN | 1 |
| Wilkins, E | 1 |
| Arvieux, C; Tribut, O | 1 |
| James, JS | 1 |
| Dal-Ré, R; Luque, I; Morejón, E; Pedromingo, A | 1 |
| Elston, R; Kleinkauf, N; Schürmann, D; Suttorp, N; Wünsche, T; Xu, F | 1 |
| Girault, V | 1 |
| Bhatti, L; Farthing, C; Khanlou, H | 1 |
| Shelton, MJ; Studenberg, S; Wire, MB | 1 |
| Adamkiewicz, B; Lou, Y; Min, SS; Shelton, MJ; Wire, MB | 1 |
| Anderson, PL; Fletcher, CV; Kiser, JJ; Lichtenstein, KA | 1 |
| Baker, KL; Berrey, MM; Jones, LS; Lou, Y; Shelton, MJ; Thomas, GJ; Wire, MB | 1 |
| Borland, J; Ford, SL; Lou, Y; Min, SS; Shelton, MJ; Wire, MB; Xue, ZG; Yuen, G | 1 |
| Bonora, S; Cocchi, S; Codeluppi, M; Di Benedetto, F; Esposito, R; Gennari, W; Gerunda, GE; Guaraldi, G; Luzi, K; Masetti, M; Motta, A; Pecorari, M | 1 |
| DeJesus, E; Elston, R; Garris, C; Gathe, JC; Givens, N; Gladysz, A; Sanne, I; Schürmann, D; Wood, R; Yeo, J | 1 |
| Piacenti, FJ | 1 |
| Corbett, AH; Eron, JJ; Kalvass, LA; Kashuba, AD; Lim, ML; Ngo, LT; Patterson, KB; Tien, HC | 1 |
| DeJesus, E; Eron, J; Estrada, V; Gathe, J; Katlama, C; Lackey, P; Patel, L; Shaefer, M; Staszewski, S; Sutherland-Phillips, D; Vavro, C; Wannamaker, P; Yau, L; Yeni, P; Yeo, J; Young, B | 1 |
| DeJesus, E; Lou, Y; Masterman, A; Min, SS; Piliero, PJ; Shelton, MJ; Stein, DS; Summers, K; Wire, MB | 1 |
| Borges-Gonzalez, S; Flockhart, D; Preskorn, SH | 1 |
| Lancaster, CT; Lou, Y; Luber, AD; Pappa, KA; Ruane, PJ; Shelton, MJ; Wire, MB | 1 |
| Augustijns, P; Brouwers, J; Tack, J | 2 |
| Sax, PE | 2 |
| Boucher, S; Breilh, D; Coureau, G; Dabis, F; Fleury, H; Lacoste, D; Lazaro, E; Merel, P; Neau, D; Pellegrin, I; Pellegrin, JL; Saux, MC; Thiébaut, R | 1 |
| Arduino, RC; Barnett, BJ; Torres, HA | 1 |
| Ballow, CH; Borland, J; Lewis, EW; Lin, J; Lou, Y; Shelton, MJ; Wire, MB; Yuen, G | 1 |
| Banik, N; Breske, A; Kruse, G; Kurowski, M; Mazur, D; Richter, H; Stocker, H; Walli, RK | 1 |
| Acosta, EP; Jennings, HC; Parks, DA; Taylor, CW | 1 |
| Arduino, RC; Torres, HA | 1 |
| Bastiani, E; Benedetti, F; Berti, F; Campaner, P; Donadel, E; Montagna, M; Regazzi, M; Rinaldi, S; Savoini, A; Venturini, R | 1 |
| Castagna, A; De Bona, A; Dorigatti, F; Galli, L; Gentilini, G; Gianotti, N; Lazzarin, A; Schira, G; Seminari, E; Soldarini, A; Uberti-Foppa, C | 1 |
| Bacarelli, A; Cauda, R; Colafigli, M; De Luca, A; Di Giambenedetto, S; Gatti, G; Pinnetti, C; Prosperi, M | 1 |
| Brower, R; Frank, I; Kim, D; Luber, AD; Peloquin, CA; Silverman, R | 1 |
| Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R | 1 |
| Blenke, AA; Burger, DM; Koopmans, PP; Pharo, C; Rongen, GA; van der Lee, MJ; Verwey-van Wissen, CP | 1 |
| Barditch-Crovo, P; Carson, KA; Flexner, C; Hendrix, CW; Khan, W; Pakes, GE; Parish, M; Parsons, T; Pham, PA; Qaqish, R; Radebaugh, C | 1 |
| Borland, J; Chen, YC; Ford, SL; Lou, Y; Min, SS; Shelton, MJ; Yuen, GJ | 1 |
| Acosta, EP; Easley, KA; Lennox, JL; Ofotokun, I; Pan, Y | 1 |
| Allavena, C; Biron, C; Dailly, E; Jolliet, P; Raffi, F | 1 |
| Delgado, O; Murillas, J; Riera, M; Ventayol, P | 1 |
| Antoun, Z; Assoumou, KL; Bocket, L; Brun-Vézinet, F; Charpentier, C; Costagliola, D; Cottalorda, J; Descamps, D; Marcelin, AG; Masquelier, B; Morand-Joubert, L; Peytavin, G; Ruffault, A; Tamalet, C | 1 |
| Bain, AM; Bedimo, RG; Busti, AJ; Hall, RG; Leff, RD; Meek, C; Mehvar, R | 1 |
| Bigelow, GE; Cao, YJ; Causon, RC; Fuchs, EJ; Hendrix, CW; Lancaster, CT; Lou, Y; Martinez, E; McCabe, S; Radebaugh, C; Smith, PF; Wire, MB | 1 |
| Calza, L; Chiodo, F; Manfredi, R; Pocaterra, D | 1 |
| Adani, GL; Bresadola, V; Furlanut, M; Londero, A; Pavan, F; Pea, F; Tavio, M; Viale, P | 1 |
| Ait-Khaled, M; Antoun, Z; Calvez, V; Flandre, P; Katlama, C; Marcelin, AG; Molina, JM; Raffi, F; Yeni, P | 1 |
| Burty, C; Christian, B; Ghomari, K; May, T; Pavel, S; Pouaha, J; Rabaud, C; Vermersch, A; Yazdanpanah, Y | 1 |
| Abbasi, NR; Wang, N | 1 |
| Bonora, S; Carosi, G; de Requena, DG; Gatti, F; Loregian, A; Matti, A; Nasta, P; Pagni, S; Palù, G; Parisi, SG; Prestini, K; Puoti, M | 1 |
| Luque, I; Mallolas, J; Pérez-Elias, MJ; Rodríguez-Alcántara, F; Sánchez-Conde, M; Soriano, V | 1 |
| Gills Ray, VL; Lee, H; Silkiss, RZ | 1 |
| Corsini, F; Lanzafame, M; Lattuada, E | 1 |
| DeJesus, E; Hicks, CB; Lancaster, CT; Liao, Q; Pakes, GE; Pappa, KA; Ross, LL; Sension, MG; Sloan, LM; Wohl, DA | 1 |
| Aboulker, JP; Bentata, M; Brun-Vézinet, F; Capitant, C; Chazallon, C; Descamps, D; Katlama, C; Landman, R; Peytavin, G; Pialoux, G; Yéni, P | 1 |
| Gatanaga, H; Goto, K; Honda, H; Honda, M; Kamimura, M; Kikuchi, Y; Matsumura, J; Oka, S; Teruya, K; Tsukada, K | 1 |
| Ait-Khaled, M; Barbosa, I; Baril, JG; Cauda, R; Craig, C; Givens, N; Lou, Y; Molina, JM; Nichols, WG; Penco, G; Pialoux, G; Rinaldi, R; Soriano, V; Wire, MB; Yeo, J | 1 |
| Anderson, PL; Clay, PG; Glaros, AG; McRae, M | 1 |
| Clotet, B; Felizarta, F; Gutiérrez, F; Hernández-Quero, J; Lou, Y; Morellon, ML; Nichols, G; Ortega, E; Pérez-Elías, MJ; Pineda, JA; Rodríguez-Torres, M; Wire, MB | 1 |
| Atripaldi, L; D'Antonio, A; Perrella, A; Perrella, O; Sbreglia, C | 1 |
| Andrews, M; Condoluci, DV; Luber, AD; Olson, K; Pakes, GE; Pappa, KA; Peloquin, CA; Slowinski, PD | 1 |
| Gumustas, M; Ozkan, SA | 1 |
| Briz, V; de José, MI; de Ory, SJ; González-Tomé, MI; León Leal, JA; Mellado, MJ; Moreno, D; Muñoz-Fernández, MA; Palladino, C; Policarpo, SN; Ramos, JT; Silveira, LF | 1 |
| Babiker, A; Fox, L; Gey, D; Lopardo, G; Markowitz, N; Paton, N; Tavel, JA; Wentworth, D; Wyman, N | 1 |
| DeJesus, E; Fischl, MA; Horton, JH; Lancaster, CT; Pakes, GE; Pappa, KA; Ross, LL; Smith, KY; Weinberg, WG | 1 |
| Corsini, F; Grosso, C; Lanzafame, M; Lattuada, E; Soldani, F; Storato, S; Vento, S | 1 |
| Fessel, WJ; Hellinger, J; Kaufman, D; Rhee, SY; Ruane, P; Shafer, RW; Shirvani, V; Taylor, J; Towner, W; Troia, P; Zolopa, A | 1 |
| Boccara, F; Costagliola, D; Cotte, L; Gilquin, J; Lang, S; Mary-Krause, M; Partisani, M; Simon, A | 1 |
| Brüggemann, RJ; Burger, DM; Colbers, EP; Pharo, C; Schouwenberg, BJ; van den Dungen, MW; van Luin, M | 1 |
| Bermudez, A; Garb, J; Kronschnabel, D; Martorell, C; Oie, K; Theroux, E | 1 |
| Bajerski, L; Bergold, AM; Dias, CL; Fröehlich, PE; Rossi, RC | 1 |
| Annaert, P; Anneveld, B; Augustijns, P; Brouwers, J; Duchateau, G; Goudappel, GJ; Zeijdner, E | 1 |
| Browning, MR; Drexler, DM; Morgan, DG; Olah, TV | 1 |
| Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF | 1 |
| Burleson, D; Gayton, JC; Laughlin, RT; Polenakovik, H | 1 |
| Cuffe, RL | 1 |
| Bogner, JR; Gyalrong-Steur, M; Seybold, U | 1 |
| Delgado-Fernández, M; García-Figueras, C; López-Cortés, LF; Macías, J; Márquez-Solero, M; Martínez-Pérez, MA; Mata, R; Merchante, N; Merino, D; Omar, M; Pasquau, J; Pineda, JA; Ríos-Villegas, MJ; Rivero, A | 1 |
| Domingo, P; Gutierrez, M; Niubó, J; Podzamczer, D; Saumoy, M; Tiraboschi, J; Vila, A | 1 |
| Alvanzo, AA; Gruber, VA; Ma, Q; McCance-Katz, EF; Moody, DE; Morse, GD; Pade, PA; Prathikanti, S; Rainey, PM | 1 |
| Arribas, JR; Estébanez, M | 1 |
| Blick, G; Dupree, D; Garton, T; Greiger-Zanlungo, P; Gretz, S; Han, J; Pakes, GE; Wine, BC; Yau, LH | 1 |
| Adorni, F; Galli, M; Giacomet, V; Mameli, C; Rusconi, S; Viganò, A; Viganò, O; Zuccotti, GV | 1 |
| Bocchiola, B; Cahua, T; Castagna, A; Danise, A; Galli, L; Gianotti, N; Lazzarin, A; Maillard, M; Panzini, P; Pazzi, A; Salpietro, S; Zandonà, D | 1 |
| Aberg, JA; Castor, D; Cespedes, MS; Ford, SL; Lee, D; Lou, Y; Pakes, GE | 1 |
| Di Nicola, M; Falasca, K; Pizzigallo, E; Ucciferri, C; Vecchiet, J; Vignale, F | 1 |
| Aguilar, A; De La Torre, J; Del Arco, A; García-Alegría, J; Olalla, J; Pombo, M; Prada, JL; Ruiz-Mateas, F; Urdiales, D | 1 |
| DeJesus, E; Edelstein, H; Felizarta, F; Ha, B; Hao, R; Huhn, G; Kumar, P; Pappa, K; Ross, L; Sloan, L; Small, CB; Stancil, B | 1 |
| Cassim, H; Cheng, K; Cotton, M; Ford, SL; Garges, HP; Givens, N; Lou, Y; Pavía-Ruz, N; Perger, T; Ross, LL; Sievers, J; Wire, MB | 1 |
| Cheng, K; Cotton, M; Duiculescu, D; Ford, SL; Fortuny, C; Garges, HP; Givens, N; Lou, Y; Perger, T; Ross, LL; Sievers, J; Tamarirt, DP; Wire, MB | 1 |
| Chilukuri, M; Hussianreddy, K; Narayanareddy, P | 1 |
| Degli Antoni, A; Ferrari, C; Fragola, V; Manfredi, R; Weimer, LE | 1 |
| Fang, A; Heera, J; Mendes da Costa, L; Plotka, A; Vourvahis, M | 1 |
| Mitra, AK; Pal, D; Patel, M; Paturi, DK; Vadlapatla, RK | 1 |
| Duong, T; Ene, L; Galli, L; Giaquinto, C; Goetghebuer, T; Judd, A; Noguera Julian, A; Pimenta, JM; Ramos Amador, JT; Thorne, C | 1 |
| Burger, DM; Colbers, AP; Jacobs, BS; Schouwenberg, BJ; Velthoven-Graafland, K | 1 |
| Borland, J; Chen, S; Peppercorn, A; Piscitelli, SC; Song, I; Wajima, T | 1 |
| Brüggemann, RJ; Burger, DM; Dolton, MJ; McLachlan, AJ | 1 |
| Barbour, AM; Gibiansky, L; Wire, MB | 1 |
| Cerini, C; Cozzi-Lepri, A; d'Arminio Monforte, A; Giralda, M; Nasta, P; Pimenta, JM; Salmon, D; Winnock, M | 1 |
| Jannuzzi, AHL; Vasconcellos, AG | 1 |
| Batkulwar, KB; Bharatam, PV; Deshpande, AY; Giri, S; Kotimoole, CN; Sahu, A; Singh, DK; Singh, S; Wani, AA | 1 |
| Augustijns, P; Braeckmans, M; Brouwers, J; Masuy, I; Servais, C; Tack, J | 1 |
| Bettio, I; Cordeiro, CF; Trevisan, MG | 1 |
| Arnold, LA; Blumin, JH; Bock, J; Goetz, CJ; Johnston, N; MacKinnon, AC; Miller, J; Ondrey, F; Samuels, TL; Seabloom, D; Silvaggi, NR; Smith, BC; Vuksanovic, N; Wiedmann, TS; Wuertz, B | 1 |
16 review(s) available for fosamprenavir and carbamates
| Article | Year |
|---|---|
From amprenavir to GW433908.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Furans; HIV Infections; Humans; Organophosphates; Prodrugs; Sulfonamides | 2001 |
Reviving protease inhibitors: new data and more options.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Furans; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Oligopeptides; Organophosphates; Pyridines; Pyrones; Sulfonamides | 2003 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Peptidomimetic inhibitors of HIV protease.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane | 2004 |
Fosamprenavir: advancing HIV protease inhibitor treatment options.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials, Phase III as Topic; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Enzyme Induction; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Prodrugs; Sulfonamides | 2004 |
Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection.
Topics: Anti-Retroviral Agents; Carbamates; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; Furans; HIV Infections; Humans; Organophosphates; Sulfonamides | 2004 |
Pharmacokinetics of Telzir (fosamprenavir).
Topics: Anti-HIV Agents; Carbamates; Drug Interactions; Drug Therapy, Combination; Furans; HIV Infections; Humans; Organophosphates; Sulfonamides | 2004 |
Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Topics: Anti-HIV Agents; Carbamates; Drug Resistance; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Ritonavir; Sulfonamides | 2005 |
[The treatment of HIV infection].
Topics: Adenine; Anti-Retroviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Therapy, Combination; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Sulfonamides; Tenofovir; Zidovudine | 2005 |
Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
Topics: Adult; Carbamates; Drug Interactions; Furans; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intestinal Absorption; Organophosphates; Prodrugs; Reverse Transcriptase Inhibitors; Sulfonamides; Tissue Distribution | 2006 |
An update and review of antiretroviral therapy.
Topics: Adenine; Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Deoxycytidine; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Drugs, Investigational; Emtricitabine; Enfuvirtide; Furans; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oligopeptides; Organophosphates; Organophosphonates; Patient Compliance; Peptide Fragments; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir | 2006 |
Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II.
Topics: Anti-HIV Agents; Antidepressive Agents; Antiparkinson Agents; Apomorphine; Atazanavir Sulfate; Azabicyclo Compounds; Carbamates; Central Nervous System Agents; Cytochrome P-450 Enzyme System; Drug Approval; Drug Interactions; Duloxetine Hydrochloride; Furans; Humans; Hypnotics and Sedatives; Indenes; Long QT Syndrome; Mental Disorders; Oligopeptides; Organophosphates; Piperazines; Psychopharmacology; Pyridines; Sulfonamides; Thiophenes | 2006 |
Fosamprenavir calcium plus ritonavir for HIV infection.
Topics: Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Exanthema; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Organophosphates; Ritonavir; Sulfonamides | 2007 |
Quality control of protease inhibitors.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides | 2008 |
Protease inhibitor monotherapy: what is its role?
Topics: Adipose Tissue; Bone Density; Carbamates; Drug Combinations; Drug Resistance, Viral; Furans; HIV Infections; Humans; Lopinavir; Organophosphates; Protease Inhibitors; Ritonavir; Sulfonamides | 2012 |
Clinically relevant drug-drug interactions between antiretrovirals and antifungals.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-Retroviral Agents; Antifungal Agents; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Drug Monitoring; Echinocandins; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Itraconazole; Mycoses; Organophosphates; Pyrimidines; Ritonavir; Sulfonamides; Triazoles; Voriconazole | 2014 |
48 trial(s) available for fosamprenavir and carbamates
| Article | Year |
|---|---|
Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers.
Topics: Adolescent; Adult; Area Under Curve; Capsules; Carbamates; Cross-Over Studies; Dose-Response Relationship, Drug; Fasting; Food-Drug Interactions; Furans; Health; Humans; Male; Middle Aged; Organophosphates; Prodrugs; Sulfonamides; Suspensions; Tablets | 2002 |
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Cross-Over Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphates; RNA, Viral; Sulfonamides | 2004 |
The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Organophosphates; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides | 2004 |
Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.
Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Carbamates; Cholesterol; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Female; Furans; Humans; Linear Models; Male; Middle Aged; Organophosphates; Oxazines; Prodrugs; Ritonavir; Sulfonamides; Triglycerides | 2004 |
GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks.
Topics: Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Follow-Up Studies; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Organophosphates; Phenotype; Ritonavir; Sulfonamides | 2004 |
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Carbamates; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nelfinavir; Organophosphates; Patient Compliance; Ritonavir; Sulfonamides | 2004 |
Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir.
Topics: Aluminum Hydroxide; Antacids; Anti-Ulcer Agents; Area Under Curve; Carbamates; Drug Administration Schedule; Drug Combinations; Drug Interactions; Furans; HIV Protease Inhibitors; Humans; Magnesium Hydroxide; Organophosphates; Ranitidine; Sulfonamides | 2005 |
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
Topics: Adult; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Salvage Therapy; Sulfonamides; Treatment Outcome | 2005 |
Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.
Topics: Adolescent; Adult; Carbamates; Clinical Trials as Topic; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides | 2006 |
Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.
Topics: Adult; Area Under Curve; Carbamates; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; Humans; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides | 2006 |
Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Topics: Adult; Aged; Carbamates; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Time | 2006 |
Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir.
Topics: Adolescent; Adult; Area Under Curve; Carbamates; Clinical Trials as Topic; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Lopinavir; Male; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides | 2006 |
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
Topics: Carbamates; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Organophosphates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2006 |
Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Interactions; Female; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2006 |
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Prodrugs; Ritonavir; Sulfonamides | 2007 |
Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state.
Topics: Administration, Oral; Adult; Carbamates; Cross-Over Studies; Duodenum; Fasting; Feasibility Studies; Female; Food-Drug Interactions; Furans; Gastric Juice; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Intestinal Secretions; Male; Organophosphates; Postprandial Period; Solubility; Sulfonamides; Tablets | 2007 |
Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.
Topics: Adolescent; Adult; Antifungal Agents; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Treatment Outcome | 2007 |
Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.
Topics: Adenine; Anti-Retroviral Agents; Area Under Curve; Carbamates; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Male; Organophosphates; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir | 2007 |
Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Area Under Curve; Carbamates; Drug Interactions; Female; Furans; Genotype; Humans; Male; Metabolic Clearance Rate; Middle Aged; Organophosphates; Paroxetine; Ritonavir; Sulfonamides | 2007 |
Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides | 2007 |
Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects.
Topics: Adult; Antitubercular Agents; Area Under Curve; Carbamates; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Furans; Humans; Male; Middle Aged; Organophosphates; Rifabutin; Ritonavir; Sulfonamides | 2008 |
Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.
Topics: Adult; Area Under Curve; Carbamates; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Furans; Half-Life; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Organophosphates; Prodrugs; Ritonavir; Sulfonamides | 2008 |
Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Carbamates; Drug Combinations; Drug Interactions; Female; Fluorobenzenes; Furans; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Oligopeptides; Organophosphates; Prospective Studies; Pyridines; Pyrimidines; Ritonavir; Rosuvastatin Calcium; Sulfonamides | 2008 |
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Topics: Adult; Anti-HIV Agents; Carbamates; Cross-Over Studies; Drug Interactions; Female; Furans; Humans; Male; Methadone; Narcotics; Organophosphates; Prodrugs; Ritonavir; Stereoisomerism; Sulfonamides | 2008 |
Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.
Topics: Adult; Anti-HIV Agents; Carbamates; Diarrhea; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease; HIV-1; Humans; Hypertriglyceridemia; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome | 2008 |
Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Female; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Mutation; Organophosphates; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
Topics: Adult; Carbamates; CD4 Lymphocyte Count; Comorbidity; Drug Therapy, Combination; Female; Fever; Furans; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Hypercholesterolemia; Hypertriglyceridemia; Male; Organophosphates; Ritonavir; RNA, Viral; Spain; Sulfonamides; Viral Load; Viremia | 2009 |
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2009 |
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asparagine; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphates; Pyridines; Quinolines; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Topics: Adult; Aged; Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
Topics: Adolescent; Adult; Aged; Atazanavir Sulfate; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Male; Middle Aged; Oligopeptides; Organophosphates; Prodrugs; Pyridines; Ritonavir; Sulfonamides | 2009 |
Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.
Topics: Adolescent; Adult; Aged; Carbamates; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Liver Diseases; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Young Adult | 2009 |
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; Cross-Over Studies; Drug Administration Schedule; Drug Eruptions; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Organophosphonates; Prodrugs; Ritonavir; Sulfonamides; Tenofovir; Young Adult | 2010 |
Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; Furans; HIV Infections; Humans; Interleukin-2; Lopinavir; Male; Nausea; Oligopeptides; Opportunistic Infections; Organophosphates; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides; Treatment Outcome | 2010 |
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Carbamates; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Furans; Genetic Variation; HIV Infections; HIV-1; Humans; Middle Aged; Oligopeptides; Organophosphates; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Sequence Analysis, RNA; Sulfonamides; Tenofovir; Treatment Failure | 2010 |
Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers.
Topics: Adolescent; Adult; Anti-HIV Agents; Antifungal Agents; Carbamates; Cross-Over Studies; Drug Interactions; Female; Furans; Healthy Volunteers; Humans; Male; Middle Aged; Organophosphates; Sulfonamides; Triazoles; Young Adult | 2010 |
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.
Topics: Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Carbamates; Confidence Intervals; Drug Administration Schedule; Drug Combinations; Dyslipidemias; Furans; HIV Infections; HIV-1; Humans; Insulin; Insulin Resistance; Lamivudine; Lipids; Lopinavir; Male; Organophosphates; Organophosphonates; Pyrimidinones; Ritonavir; Sulfonamides; Tenofovir | 2010 |
Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cohort Studies; Drug Therapy, Combination; Female; Furans; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Organophosphates; Ritonavir; RNA, Viral; Sulfonamides | 2011 |
Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.
Topics: Anti-HIV Agents; Area Under Curve; Buprenorphine; Carbamates; Darunavir; Drug Interactions; Female; Furans; Half-Life; History, 16th Century; History, 17th Century; Humans; Male; Naloxone; Narcotic Antagonists; Opiate Substitution Treatment; Organophosphates; Protease Inhibitors; Ritonavir; Sulfonamides | 2012 |
Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy.
Topics: Adult; Area Under Curve; Carbamates; Disease Transmission, Infectious; Female; Fetal Blood; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Organophosphates; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Sulfonamides; Young Adult | 2013 |
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; C-Reactive Protein; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Furans; HIV Infections; Humans; Interleukin-6; Lamivudine; Male; Middle Aged; Organophosphates; Plasminogen; Prospective Studies; Ritonavir; Sulfonamides; Vascular Cell Adhesion Molecule-1; Young Adult | 2013 |
Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data.
Topics: Carbamates; Cohort Studies; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Male; Organophosphates; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2014 |
Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.
Topics: Adolescent; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Child; Child, Preschool; Female; Furans; HIV Infections; HIV-1; Humans; Male; Organophosphates; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2014 |
Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Carbamates; Cyclohexanes; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Interactions; Furans; Humans; Male; Maraviroc; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Triazoles | 2013 |
Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers.
Topics: Adolescent; Adult; Anti-HIV Agents; Antipsychotic Agents; Benzodiazepines; Carbamates; Chromatography, Liquid; Cross-Over Studies; Drug Interactions; Female; Furans; Healthy Volunteers; Humans; Male; Middle Aged; Olanzapine; Organophosphates; Ritonavir; Serum; Spectrophotometry, Ultraviolet; Sulfonamides; Young Adult | 2014 |
Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.
Topics: Adult; Area Under Curve; Carbamates; Drug Administration Schedule; Drug Interactions; Female; Furans; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; HIV Integrase; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Organophosphates; Oxazines; Piperazines; Pyridones; Ritonavir; Sulfonamides | 2014 |
Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
Topics: Adolescent; Carbamates; Child; Child, Preschool; Computer Simulation; Drug Dosage Calculations; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Male; Models, Biological; Organophosphates; Prodrugs; Ritonavir; Sulfonamides | 2014 |
The influence of gastric motility on the intraluminal behavior of fosamprenavir.
Topics: Adult; Carbamates; Cross-Over Studies; Digestion; Duodenum; Female; Furans; Gastrointestinal Agents; Gastrointestinal Motility; Humans; Male; Middle Aged; Organophosphates; Stomach; Sulfonamides; Young Adult | 2020 |
85 other study(ies) available for fosamprenavir and carbamates
| Article | Year |
|---|---|
Phase III trials for new PI.
Topics: Antiretroviral Therapy, Highly Active; Carbamates; Chemistry, Pharmaceutical; Clinical Trials, Phase III as Topic; Dideoxynucleosides; Furans; HIV Protease Inhibitors; Humans; Lamivudine; Multicenter Studies as Topic; Nelfinavir; Organophosphates; Prodrugs; Randomized Controlled Trials as Topic; Sulfonamides | 2001 |
Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Furans; HIV Infections; Humans; Organophosphates; Structure-Activity Relationship; Sulfonamides | 2002 |
New antiretroviral agents.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Deoxycytidine; Dioxolanes; Drugs, Investigational; Emtricitabine; Furans; Guanosine; HIV Fusion Inhibitors; Humans; Imidazoles; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Prodrugs; Protease Inhibitors; Pyridines; Pyrones; Quinazolines; Reverse Transcriptase Inhibitors; Sulfonamides; Sulfur Compounds; Tenofovir | 2001 |
Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men.
Topics: Adult; Anti-HIV Agents; Carbamates; Chemistry, Pharmaceutical; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Organophosphates; Prodrugs; Ritonavir; Semen; Sulfonamides | 2002 |
Five new drugs enter the homestretch.
Topics: Carbamates; Deoxycytidine; Drug Approval; Emtricitabine; Enfuvirtide; Furans; HIV Envelope Protein gp41; HIV Protease Inhibitors; Organophosphates; Peptide Fragments; Reverse Transcriptase Inhibitors; Stavudine; Sulfonamides; United States; United States Food and Drug Administration | 2002 |
SOLO trial results released.
Topics: Carbamates; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; Humans; Nelfinavir; Organophosphates; Protease Inhibitors; Ritonavir; Sulfonamides | 2003 |
NEAT trial releases results.
Topics: Carbamates; Furans; HIV Infections; Humans; Multicenter Studies as Topic; Nelfinavir; Organophosphates; Prodrugs; Protease Inhibitors; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome; Viral Load | 2002 |
Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
Topics: Animals; Area Under Curve; Biological Availability; Carbamates; Cyclization; Drug Design; Duodenum; Furans; Half-Life; HIV Protease Inhibitors; Imides; Intestinal Absorption; Male; Organophosphates; Prodrugs; Rats; Rats, Sprague-Dawley; Solubility; Structure-Activity Relationship; Sulfonamides; Thiazoles; Water | 2003 |
Viral patterns of unboosted 908 identified.
Topics: Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Furans; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Mutation; Organophosphates; Prodrugs; Sulfonamides | 2003 |
Lexiva (fosamprenavir) approved.
Topics: Carbamates; Drug Approval; Furans; HIV Protease Inhibitors; Organophosphates; Sulfonamides; United States; United States Food and Drug Administration | 2003 |
[Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Organophosphates; Pilot Projects; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides; Time Factors; Viral Load | 2003 |
FDA grants approval to fosamprenavir calcium.
Topics: Administration, Oral; Carbamates; Drug Approval; Furans; HIV Protease Inhibitors; Organophosphates; Sulfonamides; United States; United States Food and Drug Administration | 2004 |
Drug profile: fosamprenavir (Lexiva).
Topics: Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Sulfonamides | 2003 |
Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir.
Topics: Animals; Biological Availability; Biotransformation; Caco-2 Cells; Carbamates; Dogs; Furans; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Male; Mass Spectrometry; Organophosphates; Prodrugs; Rats; Rats, Wistar; Sulfonamides | 2004 |
FDA approves Lexiva.
Topics: Carbamates; Drug Approval; Furans; HIV Protease Inhibitors; Humans; Organophosphates; Sulfonamides; United States; United States Food and Drug Administration; Viral Load | 2003 |
[Potent new protease inhibitor. Boostered protease inhibitors--a separate class of drugs].
Topics: Acquired Immunodeficiency Syndrome; Carbamates; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Organophosphates; Patient Compliance; Ritonavir; Sulfonamides; Treatment Outcome | 2003 |
[No selection of mutations. 908 raises genetic resistance barrier].
Topics: Acquired Immunodeficiency Syndrome; Carbamates; DNA Mutational Analysis; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Furans; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Nelfinavir; Organophosphates; Sulfonamides; Virus Replication | 2003 |
Fosamprenavir: a new PI option. Interview by Craig Sterritt.
Topics: Carbamates; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Reverse Transcriptase Inhibitors; Sulfonamides | 2004 |
New approaches to the industrial synthesis of HIV protease inhibitors.
Topics: Carbamates; Furans; HIV Protease Inhibitors; Molecular Conformation; Molecular Structure; Organophosphates; Sulfonamides | 2004 |
[Maintaining independence. New protease inhibitor receives drug approval recommendation].
Topics: Carbamates; Clinical Trials as Topic; Drug Administration Schedule; Drug Approval; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Europe; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Organophosphates; Sulfonamides; Viral Load | 2004 |
[FPV plus SQV plus a mini-dose ritonavir. "Double boosting with compatible partners].
Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Cross-Over Studies; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Prodrugs; Ritonavir; Saquinavir; Sulfonamides | 2004 |
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Area Under Curve; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Metabolic Clearance Rate; Middle Aged; Organophosphates; Ritonavir; RNA, Viral; Saquinavir; Sulfonamides; Viral Load | 2004 |
Lexiva: blood levels not lowered when taken simultaneously with Nexium.
Topics: Anti-HIV Agents; Carbamates; Drug Administration Schedule; Drug Interactions; Esomeprazole; Furans; HIV Infections; Humans; Organophosphates; Sulfonamides | 2005 |
[Multicentre clinical trials: degree of homogeneity in the ethical-scientific review performed by research ethics committees].
Topics: Anti-HIV Agents; Carbamates; Clinical Protocols; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Consent Forms; Ethics Committees, Research; Furans; Humans; Multicenter Studies as Topic; Organophosphates; Spain; Sulfonamides | 2005 |
Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations.
Topics: Adult; Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mutation; Organophosphates; Prodrugs; Sulfonamides | 2006 |
Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Drug Administration Schedule; Drug Interactions; Furans; HIV Infections; Humans; Oligopeptides; Organophosphates; Pyridines; Sulfonamides; Treatment Failure; Viremia | 2006 |
[Long-term virus suppression. Expanding therapy options with protease inhibitor].
Topics: Antiretroviral Therapy, Highly Active; Carbamates; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Long-Term Care; Organophosphates; Sulfonamides; Viral Load | 2005 |
Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection.
Topics: Aged; Anti-HIV Agents; Anti-Ulcer Agents; Atazanavir Sulfate; Carbamates; Drug Interactions; Esomeprazole; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Organophosphates; Prospective Studies; Proton Pump Inhibitors; Pyridines; Sulfonamides | 2006 |
Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics.
Topics: Administration, Oral; Adolescent; Adult; Carbamates; Diarrhea; Drug Administration Schedule; Drug Combinations; Esomeprazole; Female; Furans; Headache; Humans; Male; Middle Aged; Nausea; Organophosphates; Ritonavir; Sulfonamides | 2006 |
Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation.
Topics: Adult; Anti-HIV Agents; Carbamates; Furans; Hepatitis C; HIV Infections; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Metabolic Clearance Rate; Middle Aged; Organophosphates; Sulfonamides; Treatment Outcome | 2006 |
In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation.
Topics: Alkaline Phosphatase; Biological Transport; Caco-2 Cells; Carbamates; Chromatography, High Pressure Liquid; Drug Stability; Furans; HIV Protease Inhibitors; Humans; Intestinal Absorption; Intestinal Secretions; Organophosphates; Permeability; Phosphates; Phosphorylation; Prodrugs; Solubility; Sulfonamides | 2007 |
Meeting report. Report from ICAAC.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Cyclopropanes; Furans; HIV Infections; Humans; Oligopeptides; Organic Chemicals; Organophosphates; Oxazines; Patient Compliance; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Viral Load | 2006 |
Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients.
Topics: Antiretroviral Therapy, Highly Active; Carbamates; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV-1; Humans; Organophosphates; Prospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2007 |
Use of fosamprenavir, a sulfa-containing protease inhibitor, in HIV-infected patients with glucose-6-phosphate dehydrogenase deficiency.
Topics: Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Furans; Glucosephosphate Dehydrogenase Deficiency; Hemoglobins; HIV Infections; HIV Protease Inhibitors; Humans; Male; Organophosphates; Probability; Retrospective Studies; Risk Factors; Sulfonamides; Treatment Outcome | 2007 |
Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Carbamates; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Outcome | 2007 |
[Two year use of Telzir: what are the perspectives?].
Topics: Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organophosphates; Phenotype; Ritonavir; Sulfonamides | 2007 |
Development and evaluation of an immunoassay for the monitoring of the anti-HIV drug amprenavir.
Topics: Adult; Animals; Anti-HIV Agents; Antibodies; Carbamates; Chromatography, High Pressure Liquid; Cross Reactions; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Furans; Humans; Immune Sera; Molecular Structure; Organophosphates; Ovalbumin; Rabbits; Reproducibility of Results; Serum Albumin, Bovine; Sulfonamides; Vaccination | 2007 |
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Attention; Bilirubin; Carbamates; Chromatography, High Pressure Liquid; Female; Furans; HIV Infections; Humans; Liver Diseases; Male; Middle Aged; Organophosphates; Plasma; Ritonavir; Sulfonamides; Time Factors | 2007 |
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors.
Topics: Adult; Algorithms; Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance, Multiple, Viral; Female; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Organophosphates; Prevalence; Pyrimidinones; Retrospective Studies; Ritonavir; Sulfonamides | 2007 |
Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Male; Oligopeptides; Omeprazole; Organophosphates; Proton Pump Inhibitors; Pyridines; Sulfonamides | 2007 |
FDA notifications. FDA approves new formulation of Lexiva.
Topics: Adolescent; Adult; Carbamates; Child; Child, Preschool; Dosage Forms; Drug Approval; Furans; HIV Protease Inhibitors; Humans; Organophosphates; Sulfonamides; United States; United States Food and Drug Administration | 2007 |
Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Bayes Theorem; Benzoxazines; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; France; Furans; HIV Infections; Humans; Male; Models, Biological; Nevirapine; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2008 |
[Plasma levels following the switch from amprenavir to fosamprenavir in HIV-infected patients under antiretroviral treatment with lopinavir/ritonavir].
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides | 2008 |
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
Topics: Adult; Amino Acid Substitution; Carbamates; Drug Resistance, Viral; Female; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation, Missense; Organophosphates; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2008 |
Lower dose of ritonavir approved for use with fosamprenavir.
Topics: Carbamates; Dose-Response Relationship, Drug; Drug Approval; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Ritonavir; Sulfonamides; United States; United States Food and Drug Administration | 2007 |
FDA notifications. FDA approves NDA for Lexiva.
Topics: Carbamates; Drug Approval; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Sulfonamides; United States; United States Food and Drug Administration | 2007 |
FDA notifications. Fosamprenavir label is updated.
Topics: Carbamates; Drug Interactions; Drug Labeling; Furans; HIV Protease Inhibitors; Organophosphates; Sulfonamides; United States; United States Food and Drug Administration | 2008 |
Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients.
Topics: Adult; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Nelfinavir; Organophosphates; Sulfonamides; Tacrolimus | 2008 |
Tolerability of fosamprenavir/ritonavir associated with zidovudine-lamivudine used as postexposure prophylaxis for HIV infection.
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Lamivudine; Male; Organophosphates; Prospective Studies; Ritonavir; Sulfonamides; Zidovudine | 2008 |
[Individualized therapy with fosamprenavir/r. A PI suitable in liver problems].
Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Furans; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Liver Function Tests; Organophosphates; Ritonavir; Sulfonamides; Viral Load | 2008 |
Doxorubicin-induced hyperpigmentation.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Carbamates; Doxorubicin; Drug Combinations; Furans; Humans; Lamivudine; Lip Diseases; Male; Melanosis; Nails, Malformed; Organophosphates; Ritonavir; Sarcoma, Kaposi; Sulfonamides; Tongue Diseases; Zidovudine | 2008 |
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Carbamates; Chromatography, High Pressure Liquid; Elasticity Imaging Techniques; Female; Furans; Hepatitis C; HIV; HIV Infections; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Organophosphates; Plasma; Sulfonamides; Viral Load | 2009 |
Four posters add to our knowledge of Lexiva.
Topics: Carbamates; CD4 Lymphocyte Count; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Sulfonamides | 2008 |
Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blepharoptosis; Carbamates; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oculomotor Muscles; Organophosphates; Organophosphonates; Sulfonamides; Tenofovir | 2009 |
Comment on: Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
Topics: Anti-HIV Agents; Carbamates; Furans; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Organophosphates; Sulfonamides | 2009 |
Favourable use of non-boosted fosamprenavir in patients treated with warfarin.
Topics: Adult; Anti-HIV Agents; Anticoagulants; Atrial Fibrillation; Carbamates; Drug Interactions; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Japan; Male; Middle Aged; Organophosphates; Sulfonamides; Treatment Outcome; Warfarin | 2009 |
Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; Female; Furans; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-gamma; Interleukin-4; Male; Organophosphates; RNA, Viral; Sulfonamides; Transaminases; Viral Load | 2010 |
Electrochemical evaluation and determination of antiretroviral drug fosamprenavir using boron-doped diamond and glassy carbon electrodes.
Topics: Anti-HIV Agents; Boron; Carbamates; Carbon; Chromatography, High Pressure Liquid; Diamond; Electrochemistry; Electrodes; Furans; Humans; Organophosphates; Pharmaceutical Preparations; Sulfonamides | 2010 |
Long-term efficacy and safety of fosamprenavir in human immunodeficiency virus-infected pediatric patients.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; Child; Child, Preschool; Female; Furans; HIV; HIV Infections; HIV-1; Humans; Male; Organophosphates; Retrospective Studies; RNA, Viral; Statistics, Nonparametric; Sulfonamides; Viral Load | 2010 |
Heart attack warning issued.
Topics: Anti-HIV Agents; Carbamates; Furans; HIV Infections; Humans; Myocardial Infarction; Organophosphates; Sulfonamides | 2010 |
Optimal fosamprenavir regimen to prevent lipid abnormalities.
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; HIV Seropositivity; Humans; Hyperlipidemias; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Triglycerides | 2009 |
HIV-1 protease mutations and protease inhibitor cross-resistance.
Topics: Atazanavir Sulfate; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Least-Squares Analysis; Lopinavir; Mutation; Nelfinavir; Oligopeptides; Organophosphates; Polymorphism, Genetic; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides | 2010 |
Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
Topics: Adult; Anti-HIV Agents; Carbamates; Case-Control Studies; Cohort Studies; Confidence Intervals; Dideoxynucleosides; Female; France; Furans; HIV Infections; Hospitals, Isolation; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Organophosphates; Regression Analysis; Risk; Ritonavir; Sulfonamides | 2010 |
Safety and efficacy of fosamprenavir in human immunodeficiency virus-infected pregnant women.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Female; Furans; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Organophosphates; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Sulfonamides; Treatment Outcome | 2010 |
Development and validation of discriminating method of dissolution for fosamprenavir tablets based on in vivo data.
Topics: Carbamates; Chromatography, High Pressure Liquid; Drug Stability; Furans; HIV Protease Inhibitors; Humans; Organophosphates; Reproducibility of Results; Sensitivity and Specificity; Software; Solubility; Sulfonamides; Tablets | 2011 |
Food-dependent disintegration of immediate release fosamprenavir tablets: in vitro evaluation using magnetic resonance imaging and a dynamic gastrointestinal system.
Topics: Carbamates; Fasting; Food-Drug Interactions; Furans; Gastrointestinal Tract; HIV Protease Inhibitors; Humans; Magnetic Resonance Imaging; Organophosphates; Postprandial Period; Solubility; Sulfonamides; Tablets | 2011 |
Simultaneous bioanalysis of a phosphate prodrug and its parent compound using a multiplexed LC-MS method.
Topics: Animals; Carbamates; Chromatography, Liquid; Drug Stability; Furans; Hydrophobic and Hydrophilic Interactions; Male; Mass Spectrometry; Organophosphates; Phosphates; Prodrugs; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors | 2010 |
Avascular necrosis of the talus in a HIV-infected patient.
Topics: Adenine; Carbamates; Deoxycytidine; Emtricitabine; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Immunocompromised Host; Male; Middle Aged; Organophosphates; Organophosphonates; Orthotic Devices; Osteonecrosis; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Talus; Tenofovir | 2010 |
The inclusion of historical control data may reduce the power of a confirmatory study.
Topics: Bayes Theorem; Carbamates; Computer Simulation; Control Groups; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Models, Statistical; Organophosphates; Randomized Controlled Trials as Topic; Sulfonamides; Viral Load | 2011 |
Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.
Topics: Adult; Atazanavir Sulfate; Carbamates; Cholesterol; Cohort Studies; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lipid Metabolism; Male; Middle Aged; Oligopeptides; Organophosphates; Pyridines; Retrospective Studies; Saquinavir; Sulfonamides | 2011 |
Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study).
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV-1; Humans; Male; Organophosphates; Pilot Projects; Prospective Studies; Ritonavir; RNA, Viral; Spectrum Analysis; Sulfonamides; Treatment Outcome; Viral Load; Virus Replication | 2011 |
Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; Humans; Lipids; Male; Middle Aged; Organophosphates; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2012 |
Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Child; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Male; Oligopeptides; Organophosphates; Pyridines; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Treatment Outcome; Viral Load | 2012 |
Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Cross-Sectional Studies; Deoxycytidine; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Furans; HIV Infections; Humans; Italy; Lamivudine; Male; Medication Adherence; Middle Aged; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Oxazines; Pyridines; Self Report; Sulfonamides; Surveys and Questionnaires; Viral Load | 2013 |
Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy.
Topics: Adult; Anti-HIV Agents; Blood Chemical Analysis; Carbamates; CD4 Lymphocyte Count; Darunavir; Dyslipidemias; Female; Follow-Up Studies; Furans; HIV Infections; Humans; Kidney Function Tests; Liver Function Tests; Male; Metabolome; Middle Aged; Organophosphates; Prospective Studies; Protease Inhibitors; Ritonavir; Sulfonamides; White People | 2013 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Comorbidity; Cross-Sectional Studies; Cyclopropanes; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Echocardiography; Female; Furans; HIV Infections; Humans; Hypertension; Hypertrophy, Left Ventricular; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Ritonavir; Smoking; Spain; Sulfonamides; Tenofovir; Zidovudine | 2013 |
Stability-indicating HPLC method for determination of fosamprenavir calcium.
Topics: Carbamates; Chromatography, High Pressure Liquid; Drug Stability; Furans; Organophosphates; Reproducibility of Results; Sulfonamides | 2014 |
A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probab
Topics: Adult; Carbamates; Cardiomyopathies; Chemical and Drug Induced Liver Injury; Creatine Kinase; Cyclohexanes; Drug Substitution; Drug Therapy, Combination; Fatty Liver; Furans; Hepatitis C, Chronic; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Liver Cirrhosis; Male; Maraviroc; Organophosphates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Triazoles | 2012 |
Post-licensing safety of fosamprenavir in HIV-infected children in Europe.
Topics: Adolescent; Anti-HIV Agents; Carbamates; Child; Cohort Studies; Europe; Female; Follow-Up Studies; Furans; HIV Infections; Humans; Hypercholesterolemia; Male; Organophosphates; Pregnancy; Product Surveillance, Postmarketing; Retrospective Studies; Sulfonamides | 2014 |
Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.
Topics: Adult; Anti-HIV Agents; Anticonvulsants; Antiemetics; Antifungal Agents; Biological Availability; Carbamates; Drug Interactions; Drug Therapy, Combination; Furans; Healthy Volunteers; Humans; Metoclopramide; Nucleic Acid Synthesis Inhibitors; Organophosphates; Phenytoin; Proton Pump Inhibitors; Rifampin; Sulfonamides; Triazoles | 2014 |
Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Carbamates; Cause of Death; CD4 Lymphocyte Count; Coinfection; Female; Furans; Hepatitis; HIV Infections; Humans; Liver Function Tests; Male; Middle Aged; Mortality; Organophosphates; Proportional Hazards Models; Recurrence; Retrospective Studies; Risk Factors; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load | 2016 |
[How much does the backlog on drug patents cost for health in Brazil?]
Topics: Anti-Retroviral Agents; Brazil; Carbamates; Drug Industry; Drugs, Generic; Furans; Health Services Accessibility; Humans; Organophosphates; Patents as Topic; Sulfonamides | 2017 |
Stability behaviour of antiretroviral drugs and their combinations. 10: LC-HRMS, LC-MS
Topics: Anti-Retroviral Agents; Carbamates; Chromatography, High Pressure Liquid; Computer Simulation; Drug Stability; Furans; Magnetic Resonance Spectroscopy; Organophosphates; Software; Sulfonamides; Tandem Mass Spectrometry; Tissue Distribution | 2019 |
Studies on the characterization and polymorphic stability of Fosamprenavir.
Topics: Carbamates; Furans; Humidity; Microscopy, Electron, Scanning; Organophosphates; Pharmaceutical Preparations; Spectrum Analysis; Sulfonamides; Technology, Pharmaceutical; Temperature; Thermodynamics | 2020 |
Oral and Inhaled Fosamprenavir Reverses Pepsin-Induced Damage in a Laryngopharyngeal Reflux Mouse Model.
Topics: Animals; Carbamates; Furans; Laryngopharyngeal Reflux; Larynx; Mice; Pepsin A; Sulfonamides | 2023 |